0001209191-20-002630.txt : 20200108
0001209191-20-002630.hdr.sgml : 20200108
20200108201817
ACCESSION NUMBER: 0001209191-20-002630
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200107
FILED AS OF DATE: 20200108
DATE AS OF CHANGE: 20200108
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nichols Garrett
CENTRAL INDEX KEY: 0001618364
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35867
FILM NUMBER: 20516861
MAIL ADDRESS:
STREET 1: C/O CHIMERIX, INC.
STREET 2: 2505 MERIDIAN PARKWAY, SUITE 340
CITY: DURHAM
STATE: NC
ZIP: 27713
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CHIMERIX INC
CENTRAL INDEX KEY: 0001117480
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 330903395
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2505 MERIDIAN PARKWAY, SUITE 100
CITY: DURHAM
STATE: NC
ZIP: 27713
BUSINESS PHONE: 919.806.1074
MAIL ADDRESS:
STREET 1: 2505 MERIDIAN PARKWAY, SUITE 100
CITY: DURHAM
STATE: NC
ZIP: 27713
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-01-07
0
0001117480
CHIMERIX INC
CMRX
0001618364
Nichols Garrett
C/O CHIMERIX, INC.
2505 MERIDIAN PARKWAY, SUITE 100
DURHAM
NC
27713
0
1
0
0
Chief Medical Officer
Common Stock
2020-01-07
4
S
0
30680
2.1527
D
271421
D
The shares were sold in payment of the reporting person's tax liability incurred upon the vesting of shares subject to a restricted stock unit award.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.15 to $2.185, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
Includes 2,045 shares of the Issuer's common stock acquired by the reporting person on September 10, 2019 pursuant to an employee stock purchase program.
/s/ Michael Alrutz, Attorney-in-Fact
2020-01-08